Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial.
acenocoumarol
clinical trial
pharmacogenetics
venous thromboembolism
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Jun 2021
30 Jun 2021
Historique:
received:
05
05
2021
revised:
28
06
2021
accepted:
28
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Patients with venous thromboembolism (VTE) require immediate treatment with anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated the effectiveness of a dosing pharmacogenetic algorithm versus a standard-of-care dose adjustment at the beginning of acenocoumarol treatment. We included 144 patients with VTE. On the day of recruitment, a blood sample was obtained for genotyping (
Identifiants
pubmed: 34209131
pii: jcm10132949
doi: 10.3390/jcm10132949
pmc: PMC8268204
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Sanidad, Servicios Sociales e Igualdad
ID : TRA-010
Organisme : Research Institute of La Paz University Hospital
Références
Pharmacogenomics. 2013 Oct;14(13):1593-603
pubmed: 24088130
Pharmacogenomics. 2017 Jan;18(1):23-34
pubmed: 27967328
N Engl J Med. 2013 Dec 12;369(24):2294-303
pubmed: 24251363
N Engl J Med. 2013 Dec 12;369(24):2304-12
pubmed: 24251360
Circulation. 2007 Nov 27;116(22):2563-70
pubmed: 17989110
CMAJ. 2008 Jul 29;179(3):235-44
pubmed: 18663203
PLoS One. 2012;7(7):e41360
pubmed: 22911785
Eur Heart J. 2011 Aug;32(15):1909-17
pubmed: 21636598
Int J Med Sci. 2012;9(6):472-9
pubmed: 22927772
Trials. 2012 Dec 13;13:239
pubmed: 23237631
PLoS One. 2012;7(5):e37844
pubmed: 22629463
Vascul Pharmacol. 2015 Nov;74:151-157
pubmed: 26122664
Acta Cardiol Sin. 2016 Jan;32(1):1-22
pubmed: 27122927
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Clin Pharmacol Ther. 2011 Nov;90(5):701-6
pubmed: 22012312
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Thromb Haemost. 2016 Jan;115(1):117-25
pubmed: 26538428
Blood. 2005 Oct 1;106(7):2329-33
pubmed: 15947090
Clin Biochem. 2013 Jan;46(1-2):167-9
pubmed: 22917719
PLoS One. 2016 Mar 15;11(3):e0150456
pubmed: 26977927
Eur J Clin Pharmacol. 2015 Feb;71(2):173-81
pubmed: 25519826
Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491
pubmed: 30506689
PLoS One. 2010 Jun 18;5(6):e11210
pubmed: 20585445
Curr Control Trials Cardiovasc Med. 2004 Feb 18;5(1):1
pubmed: 14975176
JAMA Intern Med. 2014 Aug;174(8):1330-8
pubmed: 24935087
N Engl J Med. 2013 Dec 12;369(24):2283-93
pubmed: 24251361
J Thromb Haemost. 2014 Sep;12(9):1480-7
pubmed: 25040440
Medicine (Baltimore). 2018 Sep;97(36):e12178
pubmed: 30200121
PLoS One. 2015 Dec 16;10(12):e0144511
pubmed: 26672604
Thorax. 2013 Apr;68(4):391-3
pubmed: 23234857
Semergen. 2019 Sep;45(6):413-429
pubmed: 31331766
J Cardiovasc Pharmacol. 2019 Mar;73(3):127-135
pubmed: 30688796
Thromb Haemost. 2015 Oct;114(4):768-77
pubmed: 26158747
Clin Pharmacol Ther. 2008 Mar;83(3):460-70
pubmed: 17851566
Clin Pharmacol Ther. 2008 Sep;84(3):326-31
pubmed: 18305455
Pharmacogenomics. 2017 Feb;18(3):245-253
pubmed: 28112575
Thromb Haemost. 2013 Jan;109(1):146-53
pubmed: 23196355
JAMA. 2017 Sep 26;318(12):1115-1124
pubmed: 28973620
J Cardiovasc Pharmacol Ther. 2015 Jul;20(4):387-94
pubmed: 25575537